(ii) Spot urine albumin creatinine ratio as a measure of endothelial dysfunction.
These investigations conducted by a collaboration of highly experienced cardiologists, rheumatologists and radiologists will provide important mechanistic insights into occurrence and potential determinants of cardiovascular disease and facilitate the training of the applicant in rigorous, high quality patient centered clinical research.
41 References:
1. Power D, Codd M, Ivers L, Sant S, Barry M. Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Irish journal of medical science. 1999;168(3):197-200. Epub 1999/11/30.
2. ‘Services for People with Rheumatoid Arthritis: International Comparisons’. 2009;Availablefrom:
http://www.nao.org.uk/publications/0809/services_for_people_with_rheum.aspx. 3. Woolf AD, Akesson K. Can we reduce the burden of musculoskeletal conditions? The European action towards better musculoskeletal health. Best practice & research Clinical rheumatology. 2007;21(1):1-3. Epub 2007/03/14.
4. Cush J, Weinblatt, M. Kavanaugh, A. Rheumatoid Arthritis: Early Diagnosis and Treatment: Blackwell (Professional Communications Inc): New York; 2008. 5. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303-7. Epub 2003/03/12.
6. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? The Journal of rheumatology. 1999;26(12):2529-33. Epub 1999/12/22.
7. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? European heart journal. 2013;34(17):1262-9. Epub 2013/02/05.
8. Office CS. Vital statistics fourth quarter and yearly summary 2010. 2011. 9. Institute EaSR. Activity in acute public hospitals in Ireland: annual report 2010. 2011.
42 10. Balanda KP BS, Fahy S, McLaughlin A Making chronic conditions count: hypertension, stroke, coronary heart disease, diabetes. Institute of Public Health. Ireland. 2010.
11. Executive HS. Primary Care Reimbursement: statistical analysis of claims and payments 2009. 2011.
12. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004;109(21):2617-25. Epub 2004/06/03.
13. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. British heart journal. 1988;60(6):459-64. Epub 1988/12/01.
14. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355-74. Epub 1995/09/01.
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of medicine. 2005;352(16):1685-95. Epub 2005/04/22.
16. Ross R. Atherosclerosis--an inflammatory disease. The New England journal of medicine. 1999;340(2):115-26. Epub 1999/01/14.
17. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003;108(16):1917-23. Epub 2003/10/22.
43 18. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clinical and experimental immunology. 1995;101(2):207-12. Epub 1995/08/01. 19. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74. Epub 2002/12/20.
20. Hansson GK, Libby P. The immune response in atherosclerosis: a double- edged sword. Nature reviews Immunology. 2006;6(7):508-19. Epub 2006/06/17. 21. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96(2):396-9. Epub 1997/07/15.
22. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association. 1991;11(5):1223-30. Epub 1991/09/01. 23. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. Journal of the American College of Cardiology. 2004;43(10):1731-7. Epub 2004/05/18.
24. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arteriosclerosis, thrombosis, and vascular biology. 2013;33(7):1460-7. Epub 2013/05/21.
25. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. The American journal of cardiology. 2002;89(9):1117-9. Epub 2002/05/04.
44 26. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2010;30(12):2311-6. Epub 2010/11/19.
27. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA : the journal of the American Medical Association. 1986;256(20):2823-8. Epub 1986/11/28.
28. Romm PA, Green CE, Reagan K, Rackley CE. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. The American journal of cardiology. 1991;67(6):479-83. Epub 1991/03/01.
29. Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? Journal of cellular and molecular medicine. 2012;16(9):1978-90. Epub 2012/02/22.
30. Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Current vascular pharmacology. 2012;10(6):684-6. Epub 2012/12/25.
31. Saely CH, Rein P, Vonbank A, Huber K, Drexel H. Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. International journal of cardiology. 2013;167(3):776-80. Epub 2012/04/10.
32. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. American journal of epidemiology. 1997;146(6):483-94. Epub 1997/09/18.
45 33. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The New England journal of medicine. 1999;340(1):14-22. Epub 1999/01/08.
34. del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE, et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke; a journal of cerebral circulation. 2001;32(7):1532-8. Epub 2001/07/07.
35. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88(3):837-45. Epub 1993/09/01.
36. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109(9):1089- 94. Epub 2004/03/03.
37. Ankle Brachial Index C, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA : the journal of the American Medical Association. 2008;300(2):197-208. Epub 2008/07/10.
38. Al-Qaisi M, Kharbanda RK, Mittal TK, Donald AE. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vascular health and risk management. 2008;4(3):647-52. Epub 2008/10/02.
46 39. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91(5):1314-9. Epub 1995/03/01.
40. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. Journal of the American College of Cardiology. 1995;26(5):1235-41. Epub 1995/11/01.
41. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. The New England journal of medicine. 2000;342(24):1792-801. Epub 2000/06/15.
42. Fibrinogen Studies C, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA : the journal of the American Medical Association. 2005;294(14):1799-809. Epub 2005/10/13.
43. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996;94(9):2057-63. Epub 1996/11/01. 44. Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thrombosis research. 2008;122(6):727-35. Epub 2007/11/13.
45. Braunwald E. Chronic heart failure: a look through the rear view mirror. European heart journal. 2013;34(19):1391-2. Epub 2012/10/30.
47 47. Gary R, Davis L. Diastolic heart failure. Heart & lung : the journal of critical care. 2008;37(6):405-16. Epub 2008/11/11.
48. Oh JK SJ, Jamil Tajik A. The Echo Manual. 3rd ed2006. p. 120-1.
49. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. Journal of the American College of Cardiology. 2008;51(7):679-89. Epub 2008/02/19.
50. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. The New England journal of medicine. 2004;351(11):1097-105. Epub 2004/09/10.
51. Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmunity reviews. 2009;8(4):281-6. Epub 2008/09/27.
52. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Annals of the rheumatic diseases. 2006;65(12):1608-12. Epub 2006/06/24.
53. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis and rheumatism. 2009;61(11):1571-9. Epub 2009/10/31.
54. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis and rheumatism. 2005;52(3):722-32. Epub 2005/03/08.
55. Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Current atherosclerosis reports. 2008;10(2):128-33. Epub 2008/04/18.
48 56. Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clinical and experimental rheumatology. 2006;24(2):161-7. Epub 2006/06/10.
57. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. Hypertension in rheumatoid arthritis. Rheumatology. 2008;47(9):1286-98. Epub 2008/05/10.
58. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology. 2007;46(9):1477-82. Epub 2007/08/21.
59. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Annals of the rheumatic diseases. 2010;69(7):1342-5. Epub 2010/05/18.
60. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Annals of the rheumatic diseases. 2010;69 Suppl 1:i61-4. Epub 2010/01/09.
61. Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Panoulas VF, Douglas KM, Jamurtas AZ, et al. What predicts obesity in patients with rheumatoid arthritis? An investigation of the interactions between lifestyle and inflammation. International journal of obesity. 2010;34(2):295-301. Epub 2009/10/28.
62. Toms TE, Panoulas VF, Smith JP, Douglas KM, Metsios GS, Stavropoulos- Kalinoglou A, et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2011;70(6):1025-32. Epub 2011/03/15.
49 63. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clinical rheumatology. 2000;19(4):324-5. Epub 2000/08/15.
64. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Current vascular pharmacology. 2010;8(3):301-26. Epub 2009/09/18.
65. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. The American journal of medicine. 2006;119(6):503 e1-9. Epub 2006/06/06.
66. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint, bone, spine : revue du rhumatisme. 2011;78(2):179-83. Epub 2010/09/21.
67. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Seminars in arthritis and rheumatism. 2001;31(3):146-59. Epub 2001/12/12.
68. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Annals of the rheumatic diseases. 2008;67(1):64-9. Epub 2007/05/23.
69. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis research & therapy. 2006;8(6):R186. Epub 2006/12/16.
50 70. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Annals of the rheumatic diseases. 2007;66(2):208-14. Epub 2006/08/12. 71. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacobsen SJ, Roger VL, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2007;66(1):76- 80. Epub 2006/07/05.
72. Liang KP, Kremers HM, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al. Autoantibodies and the risk of cardiovascular events. The Journal of rheumatology. 2009;36(11):2462-9. Epub 2009/10/17.
73. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis and rheumatism. 2009;61(11):1580-5. Epub 2009/10/31.
74. Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Annals of the rheumatic diseases. 2010;69(9):1649-54. Epub 2009/07/25.
75. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. The Journal of rheumatology. 2004;31(5):867-74. Epub 2004/05/05.
76. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. The Journal of rheumatology. 2007;34(9):1810-6. Epub 2007/08/19.
51 77. Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non- steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Annals of the rheumatic diseases. 2009;68(3):367-72. Epub 2008/04/15.
78. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. The American journal of cardiology. 2011;108(9):1362- 70. Epub 2011/08/23.
79. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti- tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis care & research. 2011;63(4):522-9. Epub 2010/10/20.
80. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature medicine. 2003;9(10):1245-50. Epub 2003/10/02.
81. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clinical rheumatology. 2007;26(9):1495-8. Epub 2007/01/24.
82. Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clinica chimica acta; international journal of clinical chemistry. 2006;365(1-2):143-8. Epub 2005/09/24.
83. Del Porto F, Lagana B, Lai S, Nofroni I, Tinti F, Vitale M, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid
52 intima-media thickness in patients with active rheumatoid arthritis. Rheumatology. 2007;46(7):1111-5. Epub 2007/04/24.
84. Tikiz H, Arslan O, Pirildar T, Tikiz C, Bayindir P. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology. 2010;10(2):98-103. Epub 2010/04/13.
85. Mazzoccoli G, Notarsanto I, de Pinto GD, Dagostino MP, De Cata A, D'Alessandro G, et al. Anti-tumor necrosis factor-alpha therapy and changes of flow- mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Internal and emergency medicine. 2010;5(6):495-500. Epub 2010/09/17.
86. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis and rheumatism. 1999;42(4):757-62. Epub 1999/04/22.
87. Turesson C, Schaid DJ, Weyand CM, Jacobsson LT, Goronzy JJ, Petersson IF, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis research & therapy. 2005;7(6):R1386-93. Epub 2005/11/10.
88. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis and rheumatism. 2008;58(2):359-69. Epub 2008/02/02.
89. van Sijl AM, Peters MJ, Knol DK, de Vet HC, Gonzalez-Gay MA, Smulders YM, et al. Carotid intima media thickness in rheumatoid arthritis as compared to
53 control subjects: a meta-analysis. Seminars in arthritis and rheumatism. 2011;40(5):389-97. Epub 2010/10/05.
90. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Seminars in arthritis and rheumatism. 2012;41(5):669-75. Epub 2011/11/01.
91. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Annals of internal medicine. 2006;144(4):249-56. Epub 2006/02/24.
92. Pieringer H, Schumacher S, Stuby U, Biesenbach G. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Seminars in arthritis and rheumatism. 2009;39(3):163-9. Epub 2008/10/01.
93. Nagata-Sakurai M, Inaba M, Goto H, Kumeda Y, Furumitsu Y, Inui K, et al. Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis and rheumatism. 2003;48(11):3061-7. Epub 2003/11/13.
94. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine. 2003;82(6):407-13. Epub 2003/12/10.
95. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis research & therapy. 2007;9(6):R116. Epub 2007/11/08.
54 96. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima- media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Seminars in arthritis and rheumatism. 2009;38(5):366-71. Epub 2008/03/14.
97. Guellec D, Bressollette L, Gueguen F, Jousse-Joulin S, Marhadour T, Devauchelle-Pensec V, et al. Is routine ankle-brachial pressure index evaluation useful in rheumatoid arthritis? Joint, bone, spine : revue du rhumatisme. 2013;80(1):111-3. Epub 2012/07/31.
98. del Rincon I, Haas RW, Pogosian S, Escalante A. Lower limb arterial incompressibility and obstruction in rheumatoid arthritis. Annals of the rheumatic diseases. 2005;64(3):425-32. Epub 2004/07/24.
99. Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis and rheumatism. 2012;64(1):53-61. Epub 2011/09/10.
100. Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis research & therapy. 2009;11(2):R51. Epub 2009/04/07.
101. Sarli B, Baktir AO, Cebicci M, Dogan Y, Demirbas M, Kurtul S, et al. Predictors of Endothelial Dysfunction in Patients With Rheumatoid Arthritis. Angiology. 2013. Epub 2013/10/01.
102. Sandoo A, Kitas GD, Carroll D, Veldhuijzen van Zanten JJ. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis research & therapy. 2012;14(3):R117. Epub 2012/05/19.
55 103. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clinical rheumatology. 2008;27(7):833-9. Epub 2007/12/14.
104. Pedersen LM, Nordin H, Svensson B, Bliddal H. Microalbuminuria in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 1995;54(3):189- 92. Epub 1995/03/01.
105. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, Marinou K, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. International journal of cardiology. 2007;115(2):203-7. Epub 2006/06/22.
106. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke; a journal of cerebral circulation. 2000;31(1):26-32. Epub 2000/01/08.
107. Dimitroulas T, Douglas KM, Panoulas VF, Toms T, Smith JP, Treharne GJ, et al. Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors. Clinical rheumatology. 2013;32(9):1357-64. Epub 2013/05/16.
108. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa- Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. The Journal of rheumatology. 2002;29(5):875-82. Epub 2002/05/23.
56 109. Kamper EF, Kopeikina LT, Trontzas P, Potamianou A, Tsiroglou E, Stavridis JC. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis. The Journal of rheumatology. 2000;27(11):2545-50. Epub 2000/11/28.
110. Sodergren A, Karp K, Boman K, Eriksson C, Lundstrom E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis research & therapy. 2010;12(4):R158. Epub 2010/08/18.
111. Udayakumar N, Venkatesan S, Rajendiran C. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease. Singapore medical journal. 2007;48(6):537-42. Epub 2007/06/01.
112. Wislowska M, Jaszczyk B, Kochmanski M, Sypula S, Sztechman M. Diastolic heart function in RA patients. Rheumatology international. 2008;28(6):513-9. Epub 2007/10/25.
113. Rexhepaj N, Bajraktari G, Berisha I, Beqiri A, Shatri F, Hima F, et al. Left and right ventricular diastolic functions in patients with rheumatoid arthritis without clinically evident cardiovascular disease. International journal of clinical practice. 2006;60(6):683-8. Epub 2006/06/30.
114. Davis JM, 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis and rheumatism.